Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Immune Cell Therapy + LHRH-a in mCRPC
NCT03085966Phase 2Unknown
- Sponsor
- AbelZeta
- Start
- Feb 2017
- Primary completion
- Oct 2019
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in metastatic castration-resistant prostate cancer (mCRPC), sponsored by AbelZeta. Primary endpoint: Adverse Events and Serious Adverse Events at 24 months. Status: unknown.
02
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03085966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03085966.